Prospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Aug 14, 2021; 27(30): 5112-5125
Published online Aug 14, 2021. doi: 10.3748/wjg.v27.i30.5112
Table 4 Baseline characteristics and analyses of factors associated with the presence of subclinical atherosclerosis of patients with hepatitis B virus infection

Subclinical atherosclerosis
No subclinical atherosclerosis
Univariate analysis
Multivariate analysis
Adjusted multivariate analysis
n = 49
n = 152
P value
OR (95%CI)
P value
OR (95%CI)
P value
Age, yr57 (53.5-62.0)42 (33.0-52.0)< 0.0011.10 (1.06-1.16)< 0.0011.19 (1.12-1.25)< 0.001
Age > 50 yr (%)45 (91.8)46 (30.3)< 0.00121.9 (6.7-71.8)< 0.001
Male sex (%)31 (63.3)84 (55.3)0.207--
BMI, kg/m270.0 (64-77)69.5 (62-80)0.261--
Central obesity (%)13 (26.5)24 (16.0)0.079-0.2980.356
Tobacco exposure (%)22 (44.9)38 (25.2)0.008-0.2080.920
Alcohol intake1 (%)14 (28.5)20 (13.5)0.016-0.8760.092
Arterial hypertension (%)18 (36.7)20 (13.2)0.001-0.7890.419
Diabetes mellitus (%)5 (10.2)5 (3.3)0.067-0.9940.457
Dyslipidemia (%)16 (32.6)18 (11.9)0.001-0.8760.786
Chronic hepatitis B (%)20 (40.8)28 (18.4)0.0023.35 (1.20-9.10)0.0171.89 (1.75-2.04)< 0.001
Liver cirrhosis (%)5 (10.2)7 (4.6)0.138--
ALT, IU/mL29 (22.0-43.5)24 (17.0-34.0)0.310---
ALT > ULN (%)10 (20.4)22 (14.5)0.220--
GGT, IU/mL31 (18.0-62.5)20 (16.0-28.0)< 0.001-0.120
GGT > ULN (%)16 (32.7)8 (5.3)< 0.0015.90 (1.60-21.40)0.0071.27 (1.19-1.36)< 0.001
HbA1c, %5.5 (5.3-5.8)5.4 (5.1-5.6)0.004-0.780.551
HbA1c ≥ 6% (%)7 (14.6)6 (4.1)0.018--
HOMA index3.3 (2.2-6.0)2.4 (1.7-3.6)0.038-0.054
HOMA index > 3 (%)22 (45.8)51 (34.2)0.102--
HBsAg, logIU/mL3.2 (2.5-3.6)3.3 (2.4-4.0)0.321--
HBV DNA, logIU/mL3.1(2.4-3.8)2.9 (2.3-3.5)0.533--
Transient elastography, kPa6.2(4.2-10.3)5.2 (4.2-6.9)0.059--0.3271.01 (1.00-1.01)< 0.001
CAP, dB/m246 (210.0-289.0)213 (185.0-261.5)0.004--0.2201.000 (1.000-1.001)0.006
CAP > 227 dB/m (%)29 (67.4)51 (38.3)0.001--0.172